Long-Term Outcome of Patients with Metastatic Breast Cancer Treated with High-Dose Chemotherapy and Transplantation of Purified Autologous Hematopoietic Stem Cells

Biology of Blood and Marrow Transplantation

Volumn 18, Issue 1, 2012, Pages 125-133

  Müller, Antonia M S ^a   Kohrt, Holbrook E K ^a   Cha, Steven ^a   Laport, Ginna ^a   Klein, Jared ^b   Guardino, Alice E ^a   Johnston, Laura J ^a   Stockerl Goldstein, Keith E ^c   Hanania, Elie ^d   Juttner, Christopher ^e   Blume, Karl G ^a   Negrin, Robert S ^a   Weissman, Irving L ^f   Shizuru, Judith A ^a,f  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Banner Pediatric Specialists Hematology and Oncology   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d SAFC   (United States)

^e Australian Stem Cell Centre   (Australia)

^f Stanford California and Cofounder   (United States)

Author keywords

Hematopoietic stem cell; High dose chemotherapy; Long term; Metastatic breast cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER LOCALIZATION; CANCER PATIENT; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CD34 SELECTION; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; DRUG MEGADOSE; ENGRAFTMENT; FEASIBILITY STUDY; FEMALE; FOLLOW UP; HEMATOPOIETIC SYSTEM; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; MULTIPLE ORGAN FAILURE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PNEUMONIA; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SEPSIS; TUMOR GROWTH;

ADULT; BREAST NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84855425458     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2011.07.009     Document Type: Article

References (42)

1. Armitage J.O. The history of autologous hematopoietic cell transplantation. Thomas' Hematopoietic Cell Transplantation: Stem Cell Transplantation 2009, 8-14. Wiley Blackwell, Oxford. 4th ed. F.R. Appelbaum, S.J. Forman, R.S. Negrin, K.G. Blume (Eds.).
2. Hryniuk W., Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984, 2:1281-1288.
3. Frei E., Canellos G.P. Dose: a critical factor in cancer chemotherapy. Am J Med 1980, 69:585-594.
4. Borgen E., Naume B., Nesland J.M., et al. Standardization of theimmunocytochemical detection of cancer cells in BM and blood: I. Establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy 1999, 1:377-388.
5. Ross A.A., Cooper B.W., Lazarus H.M., et al. Detection and viability of tumor cells in peripheral blood stem cell collections from breast cancer patients using immunocytochemical and clonogenic assay techniques. Blood 1993, 82:2605-2610.
6. Fields K.K., Elfenbein G.J., Trudeau W.L., et al. Clinical significance of bone marrow metastases as detected using the polymerase chain reaction in patients with breast cancer undergoing high-dose chemotherapy and autologous bone marrow transplantation. J Clin Oncol 1996, 14:1868-1876.
7. Braun S., Vogl F.D., Naume B., et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005, 353:793-802.
8. Brugger W., Bross K.J., Glatt M., et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994, 83:636-640.
9. Burgess J., Mills B., Griffith M., et al. Breast tumor contamination of PBSC harvests: tumor depletion by positive selection of CD34(+) cells. Cytotherapy 2001, 3:285-294.
10. Negrin R.S., Atkinson K., Leemhuis T., et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with metastatic breast cancer. Biol Blood Marrow Transplant 2000, 6:262-271.
11. Pecora A.L., Lazarus H.M., Jennis A.A., et al. Breast cancer cell contamination of blood stem cell products in patients with metastatic breast cancer: predictors and clinical relevance. Biol Blood Marrow Transplant 2002, 8:536-543.
12. Passos-Coelho J.L., Ross A.A., Kahn D.J., et al. Similar breast cancer cell contamination of single-day peripheral-blood progenitor-cell collections obtained after priming with hematopoietic growth factor alone or after cyclophosphamide followed by growth factor. J Clin Oncol 1996, 14:2569-2575.
13. Franklin W.A., Glaspy J., Pflaumer S.M., et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood 1999, 94:340-347.
14. Stadtmauer E.A., Tsai D.E., Sickles C.J., et al. Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. Med Oncol 1999, 16:279-288.
15. Ferrucci P.F., Rabascio C., Gigli F., et al. A new comprehensive gene expression panel to study tumor micrometastasis in patients with high-risk breast cancer. Int J Oncol 2007, 30:955-962.
16. Vredenburgh J.J., Silva O., Broadwater G., et al. The significance of tumor contamination in the bone marrow from high-risk primary breast cancer patients treated with high-dose chemotherapy and hematopoietic support. Biol Blood Marrow Transplant 1997, 3:91-97.
17. Brockstein B.E., Ross A.A., Moss T.J., et al. Tumor cell contamination of bone marrow harvest products: clinical consequences in a cohort of advanced-stage breast cancer patients undergoing high-dose chemotherapy. J Hematother 1996, 5:617-624.
18. Cooper B.W., Moss T.J., Ross A.A., et al. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 1998, 16:3509-3517.
19. Kim M.Y., Oskarsson T., Acharyya S., et al. Tumor self-seeding by circulating cancer cells. Cell 2009, 139:1315-1326.
20. Brenner M.K., Rill D.R., Moen R.C., et al. Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. Lancet 1993, 341:85-86.
21. Rill D.R., Santana V.M., Roberts W.M., et al. Direct demonstration that autologous bone marrow transplantation for solid tumors can return a multiplicity of tumorigenic cells. Blood 1994, 84:380-383.
22. Ayash L.J., Wheeler C., Fairclough D., et al. Prognostic factors for prolonged progression-free survival with high-dose chemotherapy with autologous stem-cell support for advanced breast cancer. J Clin Oncol 1995, 13:2043-2049.
23. Elias A.D., Ibrahim J., Richardson P., et al. The impact of induction duration and the number of high-dose cycles on the long-term survival of women with metastatic breast cancer treated with high-dose chemotherapy with stem cell rescue: an analysisof sequential phase I/II trials from the Dana-Farber/Beth Israel STAMP program. Biol Blood Marrow Transplant 2002, 8:198-205.
24. Ghalie R., Richman C.M., Adler S.S., et al. Treatment of metastatic breast cancer with a split-course high-dose chemotherapy regimen and autologous bone marrow transplantation. J Clin Oncol 1994, 12:342-346.
25. Stadtmauer E.A., O'Neill A., Goldstein L.J., et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia Bone Marrow Transplant Group. N Engl J Med 2000, 342:1069-1076.
26. Lotz J.P., Curé H., Janvier M., et al. High-dose chemotherapy with haematopoietic stem cell transplantation for metastatic breast cancer patients: final results of the French multicentric randomised CMA/PEGASE 04 protocol. Eur J Cancer 2005, 41:71-78.
27. Biron P., Durand M., Roché H., et al. Pegase 03: a prospective randomized phase III trial of FEC with or without high-dose thiotepa, cyclophosphamide and autologous stem cell transplantation in first-line treatment of metastatic breast cancer. Bone Marrow Transplant 2008, 41:555-562.
28. Crump M., Gluck S., Tu D., et al. Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol 2008, 26:37-43.
29. Schmid P., Schippinger W., Nitsch T., et al. Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial. J Clin Oncol 2005, 23:432-440.
30. Singletary S.E., Allred C., Ashley P., et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20:3628-3636.
31. Eder J.P., Antman K., Peters W., et al. High-dose combination alkylating agent chemotherapy with autologous bone marrow support for metastatic breast cancer. J Clin Oncol 1986, 4:1592-1597.
32. Tricot G., Gazitt Y., Leemhuis T., et al. Collection, tumor contamination, and engraftment kinetics of highly purified hematopoietic progenitor cells to support high dose therapy in multiple myeloma. Blood 1998, 91:4489-4495.
33. Michallet M., Philip T., Philip I., et al. Transplantation with selected autologous peripheral blood CD34+Thy1+ hematopoietic stem cells (HSCs) in multiple myeloma: impact of HSC dose on engraftment, safety, and immune reconstitution. Exp Hematol 2000, 28:858-870.
34. Vose J.M., Bierman P.J., Lynch J.C., et al. Transplantation of highly purified CD34+Thy-1+ hematopoietic stem cells in patients with recurrent indolent non-Hodgkin's lymphoma. Biol Blood Marrow Transplant 2001, 7:680-687.
35. Vredenburgh J.J., Coniglio D., Broadwater G., et al. Consolidation with high-dose combination alkylating agents with bone marrow transplantation significantly improves disease-free survival in hormone-insensitive metastatic breast cancer in complete remission compared with intensive standard-dose chemotherapy alone. Biol Blood Marrow Transplant 2006, 12:195-203.
36. Vredenburgh J.J., Madan B., Coniglio D., et al. A randomized phase III comparative trial of immediate consolidation with high-dose chemotherapy and autologous peripheral blood progenitor cell support compared to observation with delayed consolidation in women with metastatic breast cancer and only bone metastases following intensive induction chemotherapy. Bone Marrow Transplant 2006, 37:1009-1015.
37. Kröger N., Frick M., Gluz O., et al. Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer. J Clin Oncol 2006, 24:3919-3926.
38. Crown J.P., Leyvraz S., Verrill M., et al. Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of IBDIS-I. J Clin Oncol 2004, 22:14s. (Suppl). Abstract 631.
39. Nieto Y., Shpall E.J. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?. Curr Opin Oncol 2009, 21:150-157.
40. Norton L., Massagué J. Is cancer a disease of self-seeding?. Nat Med 2006, 12:875-878.
41. Rahman Z.U., Frye D.K., Smith T.L., et al. Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 1999, 85:104-111.
42. Cheng Y.C., Ueno N.T. Improvement of survival and prospect of cure in patients with metastatic breast cancer. Breast Cancer 2011, [Epub ahead of print].